Pokaż cały numer - FPN - Farmaceutyczny PrzeglÄ d Naukowy

copyright © 2009 Grupa dr. A. R. Kwiecińskiego ISSN 1425-507313. Pridgen EM, Langer R, Farokhzad OC. Biodegradable,polymeric nanoparticle delivery systems for cancer therapy.Nanomedicine 2007; 5: 669–680.14. Peer D i wsp. Nanocarriers as an emerging platform forcancer therapy. Nature Nanotech 2007; 2: 51–60.15. Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosisand therapy: biological and clinical perspectives.Nanomedicine 2008: 1: 83–91.16. Gao X i wsp. In vivo cancer targeting and imaging withsemiconductor quantum dots. Nature Biotech 2004; 8:969–976.17. Daneshvar H i wsp. Imaging characteristics of zinc sulfideshell, cadmium telluride core quantum dots. Nanomedicine2008; 1: 21–29.18. Huang X i wsp. Gold nanoparticles: interesting opticalproperties and recent applications in cancer diagnosticsand therapy. Nanomedicine 2007; 5: 681–693.19. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel:a novel Cremphor-EL®-free formulation of paclitaxel.Nanomedicine 2007; 4: 415–423.20. Sengupta S, Sasisekharan R. Exploiting nanotechnologyto target cancer. Br J Cancer 2007; 96: 1315–1319.21. Liu G i wsp. Nanoparticle–chelator conjugates as inhibitorsof amyloid- aggregation and neurotoxicity: A noveltherapeutic approach for Alzheimer disease. Neur Lett2009; 455: 187–190.22. Singh N, Cohen CA, Rzigalinski BA. Treatment of NeurodegenerativeDisorders with Radical Nanomedicine.Ann NY Acad Sci 2007; 1122: 219–230.23. Sarmento B. i wsp. Development and characterizationof new insulin containing polysaccharide nanoparticles.Colloids Surf B Biointerfaces 2006; 53: 193–202.Adres do korespondencji:dr n. farm. Paweł SzymańskiZakład Chemii Farmaceutycznej i Analizy LekówUniwersytet Medyczny w Łodziul. Muszyńskiego 190-151 Łódźtel./fax: +48 42 677 92 50e-mail: pawel.szymanski@umed.lodz.pl41